EMERYVILLE, Calif., June 23, 2023 (GLOBE NEWSWIRE) — XOMA Corporation xomaBiotech Royalty Aggregator Announces It Has Been Added to the Russell 2000 and Russell 3000 The index after its annual reconstitution, which took effect at the close of the US markets on June 23, 2023.
FTSE Russell determines membership to its Russell indexes primarily based on objective, market-capitalization ranking, and style characteristics. Each year, the Russell Index is reconstituted to capture the 4,000 largest US stocks, ranking them by total market capitalization. Russell 2000 The index measures the performance of the small-cap segment of the US equity market and is a subset of the Russell 3000. index. Russell 2000 inclusion The index results in automatic inclusion in the Appropriate Growth and Value Style Index. The Russell Index is widely used by investment managers and institutional investors as a benchmark for index funds and for active investment strategies. Approximately $12.1 trillion in assets is benchmarked against Russell’s US Index.
About XOMA Corporation
XOMA is a biotechnology royalty aggregator that is uniquely positioned to help biotechnology companies achieve their goal of improving human health. XOMA captures the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires Future Economics, the seller receives non-disruptive, non-recourse funds that they can use to advance their internal drug candidates or for general corporate purposes. The company has an extensive and growing portfolio with more than 70 assets (assets defined as rights to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the company and its portfolio, please visit www.xoma.com,
Forward-looking Statements/Explanatory Notes
Certain statements included in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the timing and amount of potential commercial and milestone payments to XOMA . , the potential for XOMA’s portfolio of partnered programs and licensed technologies to generate substantial milestone and royalty income over time, XOMA’s business forecast, the potential expansion and accelerated growth of XOMA’s portfolio, and for this portfolio Ability to generate consistent cash flow and positive returns over time. , In some cases, you may qualify such forward-looking statements by words such as “anticipates,” “intends,” “believes,” “estimates,” “plans,” “seeks,” “projects,” “expects,” “may” But can be recognized. ,” “will,” “will,” “may” or “should,” the negative of these words or similar expressions. These forward-looking statements are not guarantees of XOMA’s performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove to be accurate, and actual results may differ materially from projected results due to certain risks inherent in the biotechnology industry, including the fact that our product candidates are still are subject to out-license agreements. Developed, and our licensees may require substantial funding to continue development that may not be available; We do not know whether any whether or not there will be a viable market; if therapeutic product candidates in which we have a royalty interest do not receive regulatory approval, our third-party licensees may not be able to market them; and the impact on the global economy as a result of the COVID-19 pandemic. Other potential risks to XOMA meeting these requirements are described in greater detail in XOMA’s most recent filings on Form 10-K and other filings with the Securities and Exchange Commission. Consider such risks carefully when considering the possibilities of XOMA. Any forward-looking statements in this press release represent XOMA’s beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law.
Explanatory note: Any reference to “portfolio” in this press release refers to milestones and/or royalty rights associated with a basket of drug products in development. Any reference to “assets” in this press release refers to milestones and/or royalty rights associated with individual drug products in development.
As of the date of this press release, all properties in XOMA’s Milestone and Royalty portfolio, except Wabismo, (faricimab) and IXINITY [coagulation factor IX (recombinant)], are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any investigational compound will become commercially available.
|XOMA Investor Contact||XOMA Media Contact|
|julian snowden||Cathy Vincent|
|XOMA Corporation||KV Consultancy & Management|
|+1 646-438-9754||+1 310-403-8951|